Managing Your Patient with Gout: A Review of Treatment Options

References

• . Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31(12):2429–2432
   PubMed Web of Science ®Google Scholar
• . Brixner DI, Ho MJ. Clinical, humanistic, and economic outcomes of gout. Am J Manag Care. 2005;11( 15 suppl):S459–S464; quiz S465–S468
   PubMed Web of Science ®Google Scholar
• . Pittman JR, Bross MH. Diagnosis and management of gout. Am Fam Physician. 1999;59(7):1799–1806, 1810
   PubMed Web of Science ®Google Scholar
• . Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum. 2004;50(8):2400–2414
   PubMed Web of Science ®Google Scholar
• . Cannella AC, Mikuls TR. Understanding treatments for gout. Am J Manag Care. 2005;11( 15 suppl):S451–S458; quiz S465–S468
   PubMed Web of Science ®Google Scholar
• . Krishnan E, Lienesch D, Kwoh CK. Gout in ambulatory care settings in the United States [published online ahead of print February 1, 2008]. J Rheumatol. 2008;35(3):498–501
   PubMed Web of Science ®Google Scholar
• . Hanly JG, Skedgel C, Sketris I,. Gout in the elderly–a population health study [published online ahead of print March 13, 2009]. J Rheumatol. 2009;36(4):822–830
   PubMed Web of Science ®Google Scholar
• . Lawrence RC, Felson DT, Helmick CG,. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(1):26–35
   PubMed Web of Science ®Google Scholar
• . Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout [published online ahead of print April 12, 2006]. Arthritis Res Ther. 2006;8( suppl 1):S2
   PubMed Web of Science ®Google Scholar
• . Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr, Saag KG. Gout epidemiology: results from the UK General Practice Research Database, 1990–1999. Ann Rheum Dis. 2005; 64(2):267–272
   PubMed Web of Science ®Google Scholar
• . Zhu Y, Pandya B, Choi H. Increasing Gout Prevalence in the US over the Last Two Decades: The National Health and Nutrition Examination Survey (NHANES). Arthr Rheum. 2010;62( suppl 10) (Abstract 2154):S901
   Google Scholar
• . Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004;31(8):1582–1587
   PubMed Web of Science ®Google Scholar
• . Wu EQ, Patel PA, Yu AP,. Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm. 2008;14(2):164–175
   PubMed Web of Science ®Google Scholar
• . Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol. 2009;15(1):3–7
   PubMed Web of Science ®Google Scholar
• . Rothenbacher D, Primatesta P, Ferreira A, Cea-Soriano L, Rodriguez LA. Frequency and risk factors of gout flares in a large population-based cohort of incident gout [published online ahead of print January 12, 2011]. Rheumatology (Oxford).
   Google Scholar
• . Lee SJ, Hirsch JD, Terkeltaub R,. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford). 2009;48(5):582–586
   PubMedGoogle Scholar
• . Sarkin AJ, Levack AE, Shieh MM,. Predictors of doctor-rated and patient-rated gout severity: gout impact scales improve assessment [published online ahead of print August 15, 2010]. J Eval Clin Pract. 2010;16(6):1244–1247
   PubMedGoogle Scholar
• . Mandell BF, Edwards NL, Sundy JS, Simkin PA, Pile JC. Preventing and treating acute gout attacks across the clinical spectrum: a roundtable discussion. Cleve Clin J Med. 2010;77( suppl 2):S2–S25
   PubMedGoogle Scholar
• . Shi Y, Mucsi AD, Ng G. Monosodium urate crystals in inflammation and immunity. Immunol Rev. 2010;233(1):203–217
   PubMedGoogle Scholar
• . Ng G, Chau EM, Shi Y. Recent developments in immune activation by uric acid crystals. [published online ahead of print May 26, 2010]. Arch Immunol Ther Exp (Warsz). 2010;58(4):273–277
   PubMed Web of Science ®Google Scholar
• . Lee SJ, Terkeltaub RA. New developments in clinically relevant mechanisms and treatment of hyperuricemia. Curr Rheumatol Rep. 2006;8(3):224–230
   PubMedGoogle Scholar
• . Liu R, Liote F, Rose DM, Merz D, Terkeltaub R. Proline-rich tyrosine kinase 2 and Src kinase signaling transduce monosodium urate crystal-induced nitric oxide production and matrix metalloproteinase 3 expression in chondrocytes. Arthritis Rheum. 2004;50(1):247–258
   PubMedGoogle Scholar
• . Liu R, Aupperle K, Terkeltaub R. Src family protein tyrosine kinase signaling mediates monosodium urate crystal-induced IL-8 expression by monocytic THP-1 cells. J Leukoc Biol. 2001;70(6):961–968
   PubMedGoogle Scholar
• . Liu R, O'Connell M, Johnson K, Pritzker K, Mackman N, Terkeltaub R. Extracellular signal-regulated kinase 1/extracellular signal-regulated kinase 2 mitogen-activated protein kinase signaling and activation of activator protein 1 and nuclear factor kappaB transcription factors play central roles in interleukin-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells. Arthritis Rheum. 2000;43(5):1145–1155
   PubMedGoogle Scholar
• . Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells [published online ahead of print September 7, 2003]. Nature. 2003;425(6957):516–521
   PubMed Web of Science ®Google Scholar
• . Cronstein BN, Molad Y, Reibman J, Balakhane E, Levin RI, Weissmann G. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest. 1995;96(2):994–1002
   PubMed Web of Science ®Google Scholar
• . Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment [published online ahead of print April 12, 2006]. Arthritis Res Ther. 2006;8( suppl 1):S3
   PubMed Web of Science ®Google Scholar
• . Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome [published online ahead of print January 11, 2006]. Nature. 2006;440(7081):237–241
   PubMed Web of Science ®Google Scholar
• . Chu SC, Yang SF, Tzang BS, Hsieh YS, Lue KH, Lu KH. Cathepsin B and cystatin C play an inflammatory role in gouty arthritis of the knee [published online ahead of print August 8, 2010]. Clin Chim Acta. 2010;411(21–22):1788–1792
   PubMedGoogle Scholar
• . Fam AG. Gout, diet, and the insulin resistance syndrome. J Rheumatol. 2002;29(7):1350–1355
   PubMed Web of Science ®Google Scholar
• . Novak S, Melkonian AK, Patel PA, Kleinman NL, Joseph-Ridge N, Brook RA. Metabolic syndrome-related conditions among people with and without gout: prevalence and resource use. Curr Med Res Opin. 2007;23(3):623–630
   PubMed Web of Science ®Google Scholar
• . Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol. 2010;6(1):30–38
   PubMed Web of Science ®Google Scholar
• . Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis. 2000;59(7):539–543
   PubMed Web of Science ®Google Scholar
• . Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109–115
   PubMed Web of Science ®Google Scholar
• . Doherty M. New insights into the epidemiology of gout. Rheumatology (Oxford). 2009;48( suppl 2):ii2–ii8
   PubMed Web of Science ®Google Scholar
• . Edwards NL. The role of hyperuricemia in vascular disorders. Curr Opin Rheumatol. 2009;21(2):132–137
   PubMedGoogle Scholar
• . Luk AJ, Simkin PA. Epidemiology of hyperuricemia and gout. Am J Manag Care. 2005;11( 15 suppl):S435–S442; quiz S465–S468
   PubMed Web of Science ®Google Scholar
• . Terkeltaub RA. Clinical practice. Gout. N Engl J Med. 2003;349(17):1647–1655
   PubMed Web of Science ®Google Scholar
• . Anker SD, Doehner W, Rauchhaus M,. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging [published online ahead of print April 21, 2003]. Circulation. 2003;107(15):1991–1997
   PubMed Web of Science ®Google Scholar
• . Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82(3):421–426
   PubMedGoogle Scholar
• . Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131(1):7–13
   PubMed Web of Science ®Google Scholar
• . Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH. Resurrection of uric acid as a causal risk factor in essential hypertension [published online ahead of print November 22, 2004]. Hypertension. 2005;45(1):18–20
   PubMedGoogle Scholar
• . Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke. 2003;34(8):1951–1956
   PubMed Web of Science ®Google Scholar
• . Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988–1994. Am J Kidney Dis. 2002;40(1):37–42
   PubMed Web of Science ®Google Scholar
• . Ghei M, Mihailescu M, Levinson D. Pathogenesis of hyperuricemia: recent advances. Curr Rheumatol Rep. 2002;4(3):270–274
   PubMedGoogle Scholar
• . Schlesinger N, Schumacher HR Jr. Gout: can management be improved? Curr Opin Rheumatol. 2001;13(3):240–244
   PubMed Web of Science ®Google Scholar
• . Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol. 2002;14(3):281–286
   PubMed Web of Science ®Google Scholar
• . Nyhan WL, O'Neill JP, Jinnah HA, Harris JC. Lesch-Nyhan Syndrome. In: Pagon RA, Bird TC, Dolan CR, eds. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 2000
   Google Scholar
• . Simmonds HA, Duley JA, Fairbanks LD, McBride MB. When to investigate for purine and pyrimidine disorders. Introduction and review of clinical and laboratory indications. J Inherit Metab Dis. 1997;20(2):214–226
   PubMed Web of Science ®Google Scholar
• . Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol. 2000;11(5):974–979
   PubMed Web of Science ®Google Scholar
• . Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yü TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20(3):895–900
   PubMed Web of Science ®Google Scholar
• . Janssens HJ, Janssen M, van de Lisdonk EH, Fransen J, van Riel PL, van Weel C. Limited validity of the American College of Rheumatology criteria for classifying patients with gout in primary care. Ann Rheum Dis. 2010;69(6):1255–1256
   PubMedGoogle Scholar
• . Malik A, Schumacher HR, Dinnella JE, Clayburne GM. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol. 2009;15(1):22–24
   PubMed Web of Science ®Google Scholar
• . Zhang W, Doherty M, Bardin T,; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312–1324
   PubMed Web of Science ®Google Scholar
• . Zhang W, Doherty M, Pascual E,; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1301–1311
   PubMed Web of Science ®Google Scholar
• . Sivera F, Aragon R, Pascual E. First metatarsophalangeal joint aspiration using a 29-gauge needle. Ann Rheum Dis. 2008;67(2):273–275
   PubMedGoogle Scholar
• . Quest Diagnostics I. Uric acid, synovial fluid #4403. 2011. http://www.questdiagnostics.com/hcp/testmenu/jsp/showTestMenu.jsp?fn=4403.html&labCode=CNL. Accessed January 27, 2011
   Google Scholar
• . Janssens HJ, Fransen J, van de Lisdonk EH, van Riel PL, van Weel C, Janssen M. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med. 2010;170(13):1120–1126
   PubMed Web of Science ®Google Scholar
• . Schlesinger N. Diagnosis of gout: clinical, laboratory, and radiologic findings. Am J Manag Care. 2005;11( 15 suppl):S443–S450; quiz S465–S468
   PubMed Web of Science ®Google Scholar
• . Schlesinger N, Baker DG, Schumacher HR Jr. Serum urate during bouts of acute gouty arthritis. J Rheumatol. 1997;24(11):2265–2266
   PubMedGoogle Scholar
• . Stamp LK, Zhu X, Dalbeth N, Jordan S, Edwards NL, Taylor W. Serum urate as a soluble biomarker in chronic gout-evidence that serum urate fulfills the OMERACT validation criteria for soluble biomarkers [published online ahead of print November 5, 2010]. Semin Arthritis Rheum.
   Google Scholar
• . Colcrys [package insert]. Philadelphia, PA; Mutual Pharma; 2010
   Google Scholar
• . Krystexxa [package insert]. East Brunswick, NJ; Savient Pharmaceuticals, Inc; 2010
   Google Scholar
• . Uloric [package insert]. Deerfield, IL; Takeda Pharmaceuticals America; 2009
   Google Scholar
• . Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008;371(9627):1854–1860
   PubMed Web of Science ®Google Scholar
• . Man CY, Cheung IT, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial [published online ahead of print February 5, 2007]. Ann Emerg Med. 2007;49(5):670–677
   PubMed Web of Science ®Google Scholar
• . Schumacher HR Jr, Chen LX. The practical management of gout. Cleve Clin J Med. 2008;75( suppl 5):S22–S25
   PubMedGoogle Scholar
• . Terkeltaub RA. Colchicine update: 2008 [published online ahead of print October 29, 2008]. Semin Arthritis Rheum. 2009;38(6):411–419
   PubMed Web of Science ®Google Scholar
• . Roddy E, Mallen CD, Hider SL, Jordan KP. Prescription and comorbidity screening following consultation for acute gout in primary care [published online ahead of print November 17, 2009]. Rheumatology (Oxford). 2010;49(1):105–111
   PubMedGoogle Scholar
• . Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med. 1987;17(3):301–304
   PubMedGoogle Scholar
• . Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060–1068
   PubMed Web of Science ®Google Scholar
• . Terkeltaub RA, Furst DE, DiGiacinto JL, Kook KA, Davis MW. Evidence basis of a novel colchicine dose reduction algorithm to predict & prevent colchicine toxicity in the presence of P-gp/CYP P450 3A4 inhibitors. [published online ahead of print April 7, 2011]. Arthritis Rheum.
   Google Scholar
• . FDA. FDA News Release: FDA orders halt to marketing of unapproved single-ingredient oral colchicine. 2010. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm227796.htm. Accessed September 30, 2010
   Google Scholar
• . FDA. Guidance for FDA Staff and Industry. Marketed Unapproved Drugs—Compliance Policy Guide. June 2006. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070290.pdf. Accessed January 4, 2011
   Google Scholar
• . Wertheimer AI, Davis MW, Lauterio TJ. A new perspective on the pharmacoeconomics of colchicine [published online ahead of print March 3, 2011]. Curr Med Res Opin.
   Google Scholar
• . Sutaria S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout–a systematic review [published online ahead of print April 21, 2006]. Rheumatology (Oxford). 2006;45(11):1422–1431
   PubMedGoogle Scholar
• . Underwood M. Diagnosis and management of gout. BMJ. 2006;332(7553):1315–1319
   PubMedGoogle Scholar
• . Rubin BR, Burton R, Navarra S,. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum. 2004;50(2):598–606
   PubMed Web of Science ®Google Scholar
• . Cheng TT, Lai HM, Chiu CK, Chem YC. A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis. Clin Ther. 2004;26(3):399–406
   PubMed Web of Science ®Google Scholar
• . Schumacher HR Jr, Boice JA, Daikh DI,. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ. 2002;324(7352):1488–1492
   PubMed Web of Science ®Google Scholar
• . Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302–1308
   PubMed Web of Science ®Google Scholar
• . Laporte JR, Ibanez L, Vidal X, Vendrell L, Leone R. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf. 2004;27(6):411–420
   PubMed Web of Science ®Google Scholar
• . Lewis SC, Langman MJ, Laporte JR, Matthews JN, Rawlins MD, Wiholm BE. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol. 2002;54(3):320–326
   PubMed Web of Science ®Google Scholar
• . Rostom A, Muir K, Dube C,. Gastrointestinal safety of cycloox-ygenase-2 inhibitors: a Cochrane Collaboration systematic review [published online ahead of print June 8, 2007]. Clin Gastroenterol Hepatol. 2007;5(7):818–828; e811–e815; quiz 768
   PubMed Web of Science ®Google Scholar
• . Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA; American Heart Association. Use of nonsteroidal anti-inflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634–1642
   PubMed Web of Science ®Google Scholar
• . Naproxen sodium [package insert]. Corona, CA: Watson Labs; 2007
   Google Scholar
• . Janssens HJ, van de Lisdonk EH, Bor H, van den Hoogen HJ, Janssen M. Gout, just a nasty event or a cardiovascular signal? A study from primary care. Fam Pract. 2003;20(4):413–416
   PubMed Web of Science ®Google Scholar
• . Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54(8):2688–2696
   PubMed Web of Science ®Google Scholar
• . Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med. 2008;168(10):1104–1110
   PubMed Web of Science ®Google Scholar
• . Fam AG. Gout in the elderly. Clinical presentation and treatment. Drugs Aging. 1998;13(3):229–243
   PubMedGoogle Scholar
• . Naproxen sodium [package insert]. Corona, CA: Watson Labs; 2007
   Google Scholar
• . Alloway JA, Moriarty MJ, Hoogland YT, Nashel DJ. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol. 1993;20(1):111–113
   PubMedGoogle Scholar
• . Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol. 1994;21(7):1325–1327
   PubMed Web of Science ®Google Scholar
• . Becker MA, Schumacher HR Jr, Wortmann RL,. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005;52(3):916–923
   PubMedGoogle Scholar
• . Becker MA, Schumacher HR Jr, Wortmann RL,. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450–2461
   PubMed Web of Science ®Google Scholar
• . Paulus HE, Schlosstein LH, Godfrey RG, Klinenberg JR, Bluestone R. Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum. 1974;17(5):609–614
   PubMedGoogle Scholar
• . Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA; American Heart Association. Use of nonsteroidal anti-inflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association [published online ahead of print February 26, 2007]. Circulation. 2007;115(12):1634–1642
   PubMed Web of Science ®Google Scholar
• . Schlesinger N, Dalbeth N, Perez-Ruiz F. Gout–what are the treatment options? Expert Opin Pharmacother. 2009;10(8):1319–1328
   PubMed Web of Science ®Google Scholar
• . Harrold LR, Andrade SE, Briesacher BA,. Adherence with urate-lowering therapies for the treatment of gout [published online ahead of print March 27, 2009]. Arthritis Res Ther. 2009;11(2):R46
   PubMed Web of Science ®Google Scholar
• . Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med. 2005;165(7):742–748
   PubMed Web of Science ®Google Scholar
• . Keenan RT, Pillinger MH. Hyperuricemia, gout, and cardiovascular disease–an important “muddle”. Bull NYU Hosp Jt Dis. 2009;67(3):285–290
   PubMedGoogle Scholar
• . Eggebeen AT. Gout: an update. Am Fam Physician. 2007;76(6):801–808
   PubMedGoogle Scholar
• . Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep. 2009;11(2):135–140
   PubMedGoogle Scholar
• . Wu X, Wakamiya M, Vaishnav S,. Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc Natl Acad Sci U S A. 1994;91(2):742–746
   PubMed Web of Science ®Google Scholar
• . Shalom R, Rimbroth S, Rozenman D, Markel A. Allopurinol-induced recurrent DRESS syndrome: pathophysiology and treatment. Ren Fail. 2008;30(3):327–329
   PubMed Web of Science ®Google Scholar
• . Hung SI, Chung WH, Liou LB,. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102(11):4134–4139
   PubMed Web of Science ®Google Scholar
• . Dainichi T, Uchi H, Moroi Y, Furue M. Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity? Dermatology. 2007;215(1):86–88
   PubMedGoogle Scholar
• . Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial. 2007;20(5):391–395
   PubMed Web of Science ®Google Scholar
• . Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76(1):47–56
   PubMed Web of Science ®Google Scholar
• . Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis. 2001;60(10):981–983
   PubMed Web of Science ®Google Scholar
• . Sarawate CA, Brewer KK, Yang W,. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81(7):925–934
   PubMed Web of Science ®Google Scholar
• . Hu M, Tomlinson B. Febuxostat in the management of hyperuricemia and chronic gout: a review. Ther Clin Risk Manag. 2008;4(6):1209–1220
   PubMedGoogle Scholar
• . Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin. 2009;25(7):1711–1719
   PubMed Web of Science ®Google Scholar
• . Schumacher HR Jr, Becker MA, Wortmann RL,. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540–1548
   PubMed Web of Science ®Google Scholar
• . Terkeltaub R. Gout in 2006: the perfect storm. Bull NYU Hosp Jt Dis. 2006;64(1–2):82–86
   PubMedGoogle Scholar
• . Reinders MK, van Roon EN, Jansen TL,. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis. 2009;68(1):51–56
   PubMed Web of Science ®Google Scholar
• . Lee MH, Graham GG, Williams KM, Day RO. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf. 2008;31(8):643–665
   PubMed Web of Science ®Google Scholar
• . Bardin T. Fenofibrate and losartan. Ann Rheum Dis. 2003;62(6):497–498
   PubMedGoogle Scholar
• . Elitek [package insert]. Bridgewater, NJ: Sanofi-Aventis US, LLC; 2009
   Google Scholar
• . Cortes J, Moore JO, Maziarz RT,. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone–results of a multicenter phase III study. J Clin Oncol. 2010;28(27):4207–4213
   PubMed Web of Science ®Google Scholar
• . Sundy JS, Becker MA, Baraf HS,; Pegloticase Phase 2 Study Investigators. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 2008;58(9):2882–2891
   PubMed Web of Science ®Google Scholar
• . Terkeltaub R. Learning how and when to employ uricase as bridge therapy in refractory gout. J Rheumatol. 2007;34(10):1955–1958
   PubMedGoogle Scholar
• . So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28
   PubMed Web of Science ®Google Scholar
• . Chen K, Fields T, Mancuso CA, Bass AR, Vasanth L. Anakinra's efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum. 2010;40(3)210–214
   PubMed Web of Science ®Google Scholar
• . Goldbach-Mansky R, Shroff SD, Wilson M,. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum. 2008;58(8):2432–2442
   PubMed Web of Science ®Google Scholar
• . Terkeltaub R, Sundy JS, Schumacher HR,. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study [published online ahead of print July 26, 2009]. Ann Rheum Dis. 2009;68(10):1613–1617
   PubMed Web of Science ®Google Scholar
• . Hoffman HM, Throne ML, Amar NJ,. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 2008;58(8):2443–2452
   PubMed Web of Science ®Google Scholar
• . So A, De Meulemeester M, Shamim T,. Canakinumab (ACZ885) vs. triamcinolone acetonide for treatment of acute flares and prevention of recurrent flares in gouty arthritis patients refractory to or contraindicated to NSAIDs and/or colchicine. Arthritis Rheum. 2009;60(12):3860. Abstract LB3864
   Google Scholar
• . Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB,; Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360(23):2416–2425
   PubMed Web of Science ®Google Scholar
• . Lasko B, Sheedy B, Hingorani V,. RDEA594, a novel uricosuric agent, significantly reduced serum urate levels and was well tolerated in a phase 2a pilot study in hyperuricemic gout patients. Arthritis Rheum. 2009;60( 10 suppl):Abstract 1105
   Google Scholar
• . Biocryst. BioCryst reports positive results from a phase 2 study of BCX4208 combined with allopurinol in patients with gout. Press release. Birmingham, AL: Biocryst; 2010
   Google Scholar
• . Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004;363(9417):1277–1281
   PubMed Web of Science ®Google Scholar
• . Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350(11):1093–1103
   PubMed Web of Science ®Google Scholar
• . Choi HK, Curhan G. Beer, liquor, and wine consumption and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2004;51(6):1023–1029
   PubMedGoogle Scholar
• . Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2005;52(1):283–289
   PubMed Web of Science ®Google Scholar
• . Peixoto MR, Monego ET, Jardim PC,. Diet and medication in the treatment of hyperuricemia in hypertensive patients. Arq Bras Cardiol. 2001;76(6):463–472
   PubMedGoogle Scholar
• . Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol. 2010;22(2):165–172
   PubMed Web of Science ®Google Scholar
• . Huang HY, Appel LJ, Choi MJ,. The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial. Arthritis Rheum. 2005;52(6):1843–1847
   PubMed Web of Science ®Google Scholar
• . Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study [published online ahead of print January 31, 2008]. BMJ. 2008;336(7639):309–312
   PubMedGoogle Scholar
• . Choi HK, Zhu Y, Mount DB. Genetics of gout. Curr Opin Rheumatol. 2010;22(2):144–151
   PubMedGoogle Scholar
• . Nakagawa T, Tuttle KR, Short RA, Johnson RJ. Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol. 2005;1(2):80–86
   PubMedGoogle Scholar
• . Williams PT. Effects of diet, physical activity and performance, and body weight on incident gout in ostensibly healthy, vigorously active men. Am J Clin Nutr. 2008;87(5):1480–1487
   PubMed Web of Science ®Google Scholar
• . Zhu Y, Zhang Y, Choi HK. The serum urate-lowering impact of weight loss among men with a high cardiovascular risk profile: the Multiple Risk Factor Intervention Trial. Rheumatology (Oxford). 2010;49(12):2391–2399
   PubMedGoogle Scholar
• . Harrold LR, Andrade SE, Briesacher B,. The dynamics of chronic gout treatment: medication gaps and return to therapy. Am J Med. 2010;123(1):54–59
   PubMed Web of Science ®Google Scholar
• . Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004;31(8):1575–1581
   PubMed Web of Science ®Google Scholar
• . Singh JA, Hodges JS, Asch SM. Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis. 2009;68(8):1265–1270
   PubMed Web of Science ®Google Scholar
• . Edwards NL. Treatment of gout in the difficult patient-transplant, and other comorbidities. Presented at: Annual Meeting of the American College of Rheumatology Symposium; April 15–17, 2011; Atlanta, GA
   Google Scholar
• . Wortmann RL. The management of gout: it should be crystal clear. J Rheumatol. 2006;33(10):1921–1922
   PubMedGoogle Scholar
• . Krishnan E. Gout and coronary artery disease: epidemiologic clues. Curr Rheumatol Rep. 2008;10(3):249–255
   PubMedGoogle Scholar